UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its ...

GlaxoSmithKline ( ($GSK) ) has released its Q2 earnings. Here is a breakdown of the information GlaxoSmithKline presented to its investors.

British pharmaceutical group GlaxoSmithKline said Wednesday that its annual performance should be better than expected, ...

Glaxo (GSK) delivered earnings and revenue surprises of +9.82% and +3.25%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and ...

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

GSK has signed a $500 million upfront licensing deal with Jiangsu Hengrui to secure global rights to its COPD drug HRS‑9821 ...

U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline's decision to discontinue a widely used asthma inhaler for children.

A global biopharmaceutical company headquartered in London announced the layoffs of 150 Massachusetts employees last week.

Hengrui Pharma partners with GSK to develop 12 innovative medicines, boosting globalization for Hengrui and expanding GSK's oncology and RI&I pipeline.

Earnings Estimate Revisions for Glaxo For the fiscal year ending December 2023, this drug developer is expected to earn $3.90 per share, which is a change of 12.7% from the year-ago reported number.

LONDON (AP) — LONDON (AP) — GSK plc (GSK) on Wednesday reported second-quarter earnings of $1.93 billion. The London-based company said it had profit of 94 cents per share. Earnings, adjusted for ...